- Email: [email protected]
5039791 Peptide fragments of tissue plasminogen activator
132
PATENTABSTRACTS
5039791 PEPTIDE FRAGMENTS OF TISSUE PLASMINOGEN ACTIVATOR
them, which arc reactive with a highly conserved epitope present on potyviruses and insignificantly reactive with other plant viruses, as well methods of using these monoclonal antibodies to detect potyviruses.
Arthur J Wittwer, Michael A Sanzo assigned to Monsanto Company
5043281
Novel peptide fragments of tissue plasminogen activator are described which have activity for inhibiting (a) the binding oftPA to human endothelial cells, and (b) the inactivation of tPA by plasminogen activator inhibitor-I (PAl-l). Six peptides or peptide amides with these activities have the sequences, numbered according to the native protein: tPA (31-55), tPA (81-105), tPA (181-205), tPA (301-325), tPA (451-475, and tPA (531-555). It is hoped that small, synthesizeable molecules which prevent the inactivation of tPA by PAI-I may provide a means for improving thc efficacy of therapeutically administered tPA or for reducing the tendency of patients with elevated plasma PAI-I concentrations to form fibrin clots.
HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS AND PROCESS FOR PRODUCING SAME Yasuhiko Masuho, Toru Sugano, Yoh-ichi Matsumoto, Shigeki Fujinaga, Tokyo, Japan assigned to Teijin Ltd Human monoclonal antibodies against cytomegalovirus. These antibodies can be advantageously used as a diagnostic, or preventive and remedy for cytomegalovirus infectious diseases.
5043288 5043157 FELINE INFECTIOUS PERITONITIS VACCINE AND METHOD OF PREPARATION Charles A Baldwin, Fredric Scott assigned to Cornell Research Foundation Inc It has now been discovered that feline infectious peritonitis virus, WSU FIPV 79-1146 can be attenuated to form a live modified vaccine against feline infectious peritonitis (FIP) which vaccine both imparts immunity and is safe, that it does not cause FIP in the feline.
IMMOBILIZE MOLECULAR BINDING PARTNERS TO CONTACT ACTIVATING SUPPORTS Marvin A Motsenbocker Molecular binding partners such as antibodies and haptens are immobilized to support materials that have the property of contact activation of blood protein coagulation. A binding partner is attached to a surface-active protein carrier and the resulting conjugate noncovalently adsorbs onto the surface of the support. The method provides for diagnostic assays of greater sensitivity and convenience.
5043263 MONOCLONAL ANTIBODIES AGAINST POTYVIRUSASSOCIATED ANTIGENS, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREFORE John Hammond, Ramon L Jordan The present invention is directed to monoclonal antibodies, and hybridomas which produce
5043353 A80789 P O L Y E T H E R
ANTIBIOTIC
Raymond C Yao, Robert L Hamill assigned to Eli Lilly and Company New polyether antibiotic A80789, its acyl ester, alkyl ester, and alkyl ether derivatives, and salts thereof, are useful as antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80789 by culture of Streptomyces hygroscopicus
PATENTABSTRACTS
5039791 PEPTIDE FRAGMENTS OF TISSUE PLASMINOGEN ACTIVATOR
them, which arc reactive with a highly conserved epitope present on potyviruses and insignificantly reactive with other plant viruses, as well methods of using these monoclonal antibodies to detect potyviruses.
Arthur J Wittwer, Michael A Sanzo assigned to Monsanto Company
5043281
Novel peptide fragments of tissue plasminogen activator are described which have activity for inhibiting (a) the binding oftPA to human endothelial cells, and (b) the inactivation of tPA by plasminogen activator inhibitor-I (PAl-l). Six peptides or peptide amides with these activities have the sequences, numbered according to the native protein: tPA (31-55), tPA (81-105), tPA (181-205), tPA (301-325), tPA (451-475, and tPA (531-555). It is hoped that small, synthesizeable molecules which prevent the inactivation of tPA by PAI-I may provide a means for improving thc efficacy of therapeutically administered tPA or for reducing the tendency of patients with elevated plasma PAI-I concentrations to form fibrin clots.
HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS AND PROCESS FOR PRODUCING SAME Yasuhiko Masuho, Toru Sugano, Yoh-ichi Matsumoto, Shigeki Fujinaga, Tokyo, Japan assigned to Teijin Ltd Human monoclonal antibodies against cytomegalovirus. These antibodies can be advantageously used as a diagnostic, or preventive and remedy for cytomegalovirus infectious diseases.
5043288 5043157 FELINE INFECTIOUS PERITONITIS VACCINE AND METHOD OF PREPARATION Charles A Baldwin, Fredric Scott assigned to Cornell Research Foundation Inc It has now been discovered that feline infectious peritonitis virus, WSU FIPV 79-1146 can be attenuated to form a live modified vaccine against feline infectious peritonitis (FIP) which vaccine both imparts immunity and is safe, that it does not cause FIP in the feline.
IMMOBILIZE MOLECULAR BINDING PARTNERS TO CONTACT ACTIVATING SUPPORTS Marvin A Motsenbocker Molecular binding partners such as antibodies and haptens are immobilized to support materials that have the property of contact activation of blood protein coagulation. A binding partner is attached to a surface-active protein carrier and the resulting conjugate noncovalently adsorbs onto the surface of the support. The method provides for diagnostic assays of greater sensitivity and convenience.
5043263 MONOCLONAL ANTIBODIES AGAINST POTYVIRUSASSOCIATED ANTIGENS, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREFORE John Hammond, Ramon L Jordan The present invention is directed to monoclonal antibodies, and hybridomas which produce
5043353 A80789 P O L Y E T H E R
ANTIBIOTIC
Raymond C Yao, Robert L Hamill assigned to Eli Lilly and Company New polyether antibiotic A80789, its acyl ester, alkyl ester, and alkyl ether derivatives, and salts thereof, are useful as antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80789 by culture of Streptomyces hygroscopicus